Solid Tumor: Clinical Trials

62 trials for Solid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

62 completed. 62 Phase 2, 39 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 262Completed 62
Phase 139Completed 39

Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor

Trials (filtered) newest first · largest first

All 62 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody - Solid Tumor
Phase 1 / Phase 2CompletedCorbus Pharmaceuticals Inc.512024-12-042026-11-17
A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
IBI129 - Solid Tumor
Phase 1 / Phase 2CompletedInnovent Biologics (Suzhou) Co. Ltd.362024-03-122026-06-24
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
favezelimab/pembrolizumab, pembrolizumab, lenvatinib - Solid Tumor, Cutaneous Squamous Cell Carcinoma
Phase 2CompletedMerck Sharp & Dohme LLC1632023-09-292026-03-19
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor
Phase 1 / Phase 2CompletedKineta Inc.402023-03-032026-10-05
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
JAB-BX102 (anti-CD73 monoclonal antibody), pembrolizumab (anti-PD-1 monoclonal antibody) - Solid Tumor
Phase 1 / Phase 2CompletedJacobio Pharmaceuticals Co., Ltd.212022-08-182026-01-06
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Afuresertib, Nab paclitaxel, Docetaxel - Solid Tumor, NSCLC
Phase 1 / Phase 2CompletedLaekna Limited222022-07-012025-11-17
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
nab-sirolimus - Tumor, Tumor, Solid
Phase 2CompletedAadi Bioscience, Inc.1282022-03-102026-10-28
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
HMPL-453, gemcitabine and cisplatin, toripalimab - Solid Tumor
Phase 1 / Phase 2CompletedHutchison Medipharma Limited1902022-01-222026-05-15
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Surufatinib in combination with Gemcitabine - Solid Tumor, Lymphoma
Phase 1 / Phase 2CompletedHutchmed132021-11-302024-06-07
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
JAB-3312, Binimetinib, Pembrolizumab - Solid Tumor, NSCLC
Phase 1 / Phase 2CompletedAllist Pharmaceuticals, Inc.582021-03-232025-04-11
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion - Solid Tumor, Non Small Cell Lung Cancer
Phase 1 / Phase 2CompletedFamewave Ltd.792021-03-192024-12-27
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
utidelone injection - Solid Tumor
Phase 2CompletedBeijing Biostar Pharmaceuticals Co., Ltd.1262021-01-222026-04-03
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
LYT-200, Tislelizumab - Metastatic Cancer, Solid Tumor
Phase 1 / Phase 2CompletedPureTech442020-12-112026-11-16
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Benralizumab - Solid Tumor, Solid Carcinoma
Phase 2CompletedMemorial Sloan Kettering Cancer Center512020-09-162026-06-01
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
COM701 in combination with BMS-986207 and nivolumab. - Endometrial Neoplasms, Ovarian Cancer
Phase 1 / Phase 2CompletedCompugen Ltd482020-08-312024-07-18
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
Camrelizumab, Famitinib - Solid Tumor
Phase 2CompletedJiangsu HengRui Medicine Co., Ltd.2332020-06-052023-09-18
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
RC88 - Solid Tumor
Phase 1 / Phase 2CompletedRemeGen Co., Ltd.1982020-04-142026-01-07
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
Porfimer Sodium, Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy - Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma
Phase 1 / Phase 2CompletedRoswell Park Cancer Institute192020-02-122026-05-14
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
IPI-549 (eganelisib), Nivolumab, Placebos - Bladder Cancer, Urothelial Carcinoma
Phase 2CompletedInfinity Pharmaceuticals, Inc.492019-09-252022-11-25
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
AK105 - Solid Tumor, Lung Cancer
Phase 1 / Phase 2CompletedAkeso652019-09-102025-03-12

Showing 20 of 62. Sign in to see all of them.

Narrower conditions

Neoplasms (11)  ·  Carcinoma, Non-Small-Cell Lung (8)  ·  Breast Neoplasms (7)  ·  Ovarian Neoplasms (7)  ·  Colorectal Neoplasms (6)  ·  Head and Neck Neoplasms (6)  ·  Lung Neoplasms (6)  ·  Melanoma (6)  ·  Neoplasm Metastasis (6)  ·  Pancreatic Neoplasms (6)  ·  Sarcoma (6)  ·  Colonic Neoplasms (5)  ·  Prostatic Neoplasms (5)  ·  Urinary Bladder Neoplasms (5)  ·  Carcinoma (4)

Broader conditions

Neoplasms by Site (34)  ·  Neoplasms (33)  ·  Neoplasms by Histologic Type (19)  ·  Digestive System Diseases (16)  ·  Digestive System Neoplasms (16)  ·  Urogenital Diseases (14)  ·  Urogenital Neoplasms (14)  ·  Female Urogenital Diseases (13)  ·  Female Urogenital Diseases and Pregnancy Complications (13)  ·  Gastrointestinal Diseases (13)  ·  Gastrointestinal Neoplasms (12)  ·  Genital Diseases (12)  ·  Neoplasms, Glandular and Epithelial (12)  ·  Colonic Diseases (10)  ·  Genital Diseases, Female (10)

Interventions

Nivolumab (9)  ·  pembrolizumab (8)  ·  Paclitaxel (6)  ·  Cisplatin (5)  ·  Cetuximab (3)  ·  Docetaxel (3)  ·  Fluorouracil (3)  ·  Gemcitabine (3)  ·  Ipilimumab (3)  ·  Capecitabine (2)  ·  Carboplatin (2)  ·  Diphenhydramine (2)  ·  Everolimus (2)  ·  Taxes (2)  ·  epacadostat (2)

Sponsors

Eli Lilly and Company (4)  ·  National Cancer Institute (NCI) (2)  ·  Samsung Medical Center (2)  ·  Aadi Bioscience, Inc. (1)  ·  Aileron Therapeutics, Inc. (1)  ·  Akeso (1)  ·  Allist Pharmaceuticals, Inc. (1)  ·  Arch Oncology (1)  ·  Asha Nayak (1)  ·  Athenex, Inc. (1)  ·  Basilea Pharmaceutica (1)  ·  Beijing Biostar Pharmaceuticals Co., Ltd. (1)  ·  Binhui Biopharmaceutical Co., Ltd. (1)  ·  Bristol-Myers Squibb (1)  ·  Celgene (1)

Countries

United States (41)  ·  China (11)  ·  South Korea (7)  ·  France (6)  ·  Spain (5)  ·  Italy (4)  ·  Australia (3)  ·  Canada (3)  ·  Taiwan (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Czechia (1)  ·  Germany (1)  ·  India (1)  ·  Israel (1)

Top investigators

Ajjai Alva, MD (1)  ·  Aleksandra Filipovic, MD, Ph.D. (1)  ·  Alfredo Urdaneta, M.D. (1)  ·  Alina Markova, MD (1)  ·  Anatolij D Namgaladze, Master (1)  ·  Asha Nayak, MD (1)  ·  Benajmin Oshrine, MD (1)  ·  Chiara Matilde Catania, Dr (1)  ·  Christian Ottensmeier, MD (1)  ·  Craig L Slingluff, Jr., MD (1)

Results publications

PMID 21739119, PMID 26095785, PMID 26984445, PMID 27240885, PMID 27627808, PMID 28196905, PMID 28330462, PMID 28972963, PMID 30227893, PMID 30420614, PMID 31401903, PMID 32107712, PMID 33431660, PMID 33602696, PMID 34230007, PMID 35165764, PMID 35633184, PMID 35724798, PMID 35833116, PMID 36156099, PMID 37415845, PMID 37507657, PMID 38388167, PMID 38538867, PMID 39089004, PMID 39872476, PMID 39915002, PMID 40232157, PMID 40333694, PMID 40847194, PMID 42165088, PMID 42498485

NIH funding

2014 (1), 2015 (1), 2016 (1), 2018 (1), 2023 (1), P30CA016059 (1), R44CA265656 (1)